Paper Citation Record · LEDGER

Statistical Operating Characteristics of Current Early Phase Dose Finding Designs with Toxicity and Efficacy in Oncology

As of 22 August 2026, this Paper Citation Record lists 38 of 38 outbound references and 0 inbound Pith citation observations for arXiv:2411.08698.

A citation records a reference. It does not transfer a finding from one paper to another.

pith.paper-citation-record.v1
2411.08698 v1

Coverage vector

measured 38 of 38 reference resolution

Typed states for the displayed outbound observations.

Source: paper_references, paper_reference_links, observed 2026-08-12T21:30:32.654756Z

measured 38 of 38 standing notices

One-hop event checks from named stored sources.

Source: scholarly_work_events, retraction_status_cache, observed 2026-08-22T06:32:14.747728+00:00

measured 0 of 0 inbound itemization

Pith citing papers itemized under the disclosed page cap.

Source: paper_references, paper_reference_links

measured 0 of 1 external citation measurements

A source-named dated measurement, never combined with another source.

Source: cited_works

Reference resolution

38 of 38 outbound references displayed

verified exact0
verified fuzzy36
unresolved1
parse uncertain0
malformed identifier1
metadata mismatch0

External citation measurements

No source-named external measurement is stored.

Outbound references

Observation 71cfbb4b-9651-451d-8445-5a08dff9a9a0 · outbound

This paper cites Contemporary dose-escalation methods for early phase studies in the im- munotherapeutics era.

Statistical Operating Characteristics of Current Early Phase Dose Finding Designs with Toxicity and Efficacy in Oncology Contemporary dose-escalation methods for early phase studies in the im- munotherapeutics era

Reference 1

Resolution: verified fuzzy; raw_fallback, observed 2026-08-12T21:30:38.954753Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-22T06:32:14.747728+00:00.

Observation 791a3f9f-51dc-44ef-ab1b-4b5915cb5f62 · outbound

This paper cites Cancer phase I clinical trials: efficient dose escalation with overdose control.

Statistical Operating Characteristics of Current Early Phase Dose Finding Designs with Toxicity and Efficacy in Oncology Cancer phase I clinical trials: efficient dose escalation with overdose control

Reference 2

Resolution: verified fuzzy; raw_fallback, observed 2026-08-12T21:30:38.794761Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-22T06:32:14.747728+00:00.

Observation 9fc6985f-f384-4f91-98be-c1c41c4fa405 · outbound

This paper cites A Bayesian dose-finding design for oncology clinical trials of combinational biological agents.

Statistical Operating Characteristics of Current Early Phase Dose Finding Designs with Toxicity and Efficacy in Oncology A Bayesian dose-finding design for oncology clinical trials of combinational biological agents

Reference 3

Resolution: verified fuzzy; raw_fallback, observed 2026-08-12T21:30:38.614753Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-22T06:32:14.747728+00:00.

Observation 588a694d-45b6-4a57-8fe9-807d38483321 · outbound

This paper cites Project optimus: Reforming the dose optimization and dose selection paradigm in oncology, 2022.

Statistical Operating Characteristics of Current Early Phase Dose Finding Designs with Toxicity and Efficacy in Oncology Project optimus: Reforming the dose optimization and dose selection paradigm in oncology, 2022

Reference 4

Resolution: verified fuzzy; raw_fallback, observed 2026-08-12T21:30:38.545415Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-22T06:32:14.747728+00:00.

Observation aa465e08-3f77-4715-80e4-c65ea2fafa5a · outbound

This paper cites an unresolved cited work.

Statistical Operating Characteristics of Current Early Phase Dose Finding Designs with Toxicity and Efficacy in Oncology Unresolved cited work

Reference 5

Resolution: unresolved; raw_fallback, observed 2026-08-12T21:30:38.414754Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-22T06:32:14.747728+00:00.

Observation 8bd3f98a-7828-4a1d-9c90-2219cb099cbb · outbound

This paper cites A Bayesian interval dose-finding design addressingockham’s razor: mTPI-2.

Statistical Operating Characteristics of Current Early Phase Dose Finding Designs with Toxicity and Efficacy in Oncology A Bayesian interval dose-finding design addressingockham’s razor: mTPI-2

Reference 6

Resolution: verified fuzzy; raw_fallback, observed 2026-08-12T21:30:38.260282Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-22T06:32:14.747728+00:00.

Observation be1e6e83-f054-4e38-85e6-292286deb63a · outbound

This paper cites Continual reassessment and related designs in dose-finding studies.

Statistical Operating Characteristics of Current Early Phase Dose Finding Designs with Toxicity and Efficacy in Oncology Continual reassessment and related designs in dose-finding studies

Reference 7

Resolution: verified fuzzy; raw_fallback, observed 2026-08-12T21:30:38.105466Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-22T06:32:14.747728+00:00.

Observation b0355a2c-c837-46f6-89cd-f3bf6a35e090 · outbound

This paper cites A modified toxicity probability interval method for dose-finding trials.

Statistical Operating Characteristics of Current Early Phase Dose Finding Designs with Toxicity and Efficacy in Oncology A modified toxicity probability interval method for dose-finding trials

Reference 8

Resolution: verified fuzzy; raw_fallback, observed 2026-08-12T21:30:37.945189Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-22T06:32:14.747728+00:00.

Observation 2e35055e-e220-4651-a9c6-839c68f7a991 · outbound

This paper cites Toxicity and efficacy probability interval design for phase I adoptive cell therapy dose-finding clinical trials.

Statistical Operating Characteristics of Current Early Phase Dose Finding Designs with Toxicity and Efficacy in Oncology Toxicity and efficacy probability interval design for phase I adoptive cell therapy dose-finding clinical trials

Reference 9

Resolution: verified fuzzy; raw_fallback, observed 2026-08-12T21:30:37.774754Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-22T06:32:14.747728+00:00.

Observation 2bb52219-670e-4453-b72a-2e4335316e52 · outbound

This paper cites TEPI-2 and UBI: designs for optimal immuno-oncology and cell therapy dose finding with toxicity and efficacy.

Statistical Operating Characteristics of Current Early Phase Dose Finding Designs with Toxicity and Efficacy in Oncology TEPI-2 and UBI: designs for optimal immuno-oncology and cell therapy dose finding with toxicity and efficacy

Reference 10

Resolution: verified fuzzy; raw_fallback, observed 2026-08-12T21:30:37.634843Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-22T06:32:14.747728+00:00.

Observation c5d2991e-98d9-4368-91ff-6d28d3de30f2 · outbound

This paper cites Comparison between simultaneous and se- quential utilization of safety and efficacy for optimal dose determination in Bayesian model-assisted designs.

Statistical Operating Characteristics of Current Early Phase Dose Finding Designs with Toxicity and Efficacy in Oncology Comparison between simultaneous and se- quential utilization of safety and efficacy for optimal dose determination in Bayesian model-assisted designs

Reference 11

Resolution: verified fuzzy; raw_fallback, observed 2026-08-12T21:30:37.484751Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-22T06:32:14.747728+00:00.

Observation 6e1cf004-557e-4b1c-bdc4-ab81dc8c6ee2 · outbound

This paper cites STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials.

Statistical Operating Characteristics of Current Early Phase Dose Finding Designs with Toxicity and Efficacy in Oncology STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials

Reference 12

Resolution: verified fuzzy; raw_fallback, observed 2026-08-12T21:30:37.304836Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-22T06:32:14.747728+00:00.

Observation 0313e8cd-c3aa-4fd7-9fdd-3dadfbdba54e · outbound

This paper cites BOIN12: Bayesian optimal interval phase i/ii trial design for utility-based dose finding in im- munotherapy and targeted therapies.

Statistical Operating Characteristics of Current Early Phase Dose Finding Designs with Toxicity and Efficacy in Oncology BOIN12: Bayesian optimal interval phase i/ii trial design for utility-based dose finding in im- munotherapy and targeted therapies

Reference 13

Resolution: verified fuzzy; raw_fallback, observed 2026-08-12T21:30:37.135685Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-22T06:32:14.747728+00:00.

Observation 06894c9f-5ca4-4816-abde-275f6ba5263f · outbound

This paper cites Probability intervals of toxicity and efficacy design for dose- finding clinical trials in oncology.

Statistical Operating Characteristics of Current Early Phase Dose Finding Designs with Toxicity and Efficacy in Oncology Probability intervals of toxicity and efficacy design for dose- finding clinical trials in oncology

Reference 14

Resolution: verified fuzzy; raw_fallback, observed 2026-08-12T21:30:36.983093Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-22T06:32:14.747728+00:00.

Observation 6d285e25-842a-4eb5-bafa-e4620d83690a · outbound

This paper cites A robust Bayesian dose-finding design for phase I/II clinical trials.

Statistical Operating Characteristics of Current Early Phase Dose Finding Designs with Toxicity and Efficacy in Oncology A robust Bayesian dose-finding design for phase I/II clinical trials

Reference 15

Resolution: verified fuzzy; raw_fallback, observed 2026-08-12T21:30:36.804754Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-22T06:32:14.747728+00:00.

Observation 424faf72-4ccd-4951-a322-0291bcbc1293 · outbound

This paper cites Bayesian optimal interval designs for phase I clinical trials.

Statistical Operating Characteristics of Current Early Phase Dose Finding Designs with Toxicity and Efficacy in Oncology Bayesian optimal interval designs for phase I clinical trials

Reference 16

Resolution: verified fuzzy; raw_fallback, observed 2026-08-12T21:30:36.614754Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-22T06:32:14.747728+00:00.

Observation 28d6d696-3108-440f-807b-2b0200b400f7 · outbound

This paper cites Serious ethical dilemma of single-agent pegylated liposomal dox- orubicin employed as a control arm in ovarian cancer chemotherapy trials.

Statistical Operating Characteristics of Current Early Phase Dose Finding Designs with Toxicity and Efficacy in Oncology Serious ethical dilemma of single-agent pegylated liposomal dox- orubicin employed as a control arm in ovarian cancer chemotherapy trials

Reference 17

Resolution: verified fuzzy; raw_fallback, observed 2026-08-12T21:30:36.465037Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-22T06:32:14.747728+00:00.

Observation fcc16289-5f35-439a-9d66-f4e43d54d814 · outbound

This paper cites Optimizing dosing of oncology drugs.

Statistical Operating Characteristics of Current Early Phase Dose Finding Designs with Toxicity and Efficacy in Oncology Optimizing dosing of oncology drugs

Reference 18

Resolution: verified fuzzy; raw_fallback, observed 2026-08-12T21:30:36.303033Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-22T06:32:14.747728+00:00.

Observation a2b2ea55-f621-43ee-9c3b-339a42d02012 · outbound

This paper cites Critical aspects of the Bayesian approach to phase I cancer trials.

Statistical Operating Characteristics of Current Early Phase Dose Finding Designs with Toxicity and Efficacy in Oncology Critical aspects of the Bayesian approach to phase I cancer trials

Reference 19

Resolution: verified fuzzy; raw_fallback, observed 2026-08-12T21:30:36.139892Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-22T06:32:14.747728+00:00.

Observation 80598ab8-56ac-4e20-b530-c034bf39179f · outbound

This paper cites Keyboard design for phase I drug-combination trials.

Statistical Operating Characteristics of Current Early Phase Dose Finding Designs with Toxicity and Efficacy in Oncology Keyboard design for phase I drug-combination trials

Reference 20

Resolution: verified fuzzy; raw_fallback, observed 2026-08-12T21:30:35.979190Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-22T06:32:14.747728+00:00.

Observation 5bdbd738-7a50-4eac-84e3-62dc7b320029 · outbound

This paper cites Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities.

Statistical Operating Characteristics of Current Early Phase Dose Finding Designs with Toxicity and Efficacy in Oncology Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities

Reference 21

Resolution: verified fuzzy; raw_fallback, observed 2026-08-12T21:30:35.804829Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-22T06:32:14.747728+00:00.

Observation 63157d38-b2b3-4005-8273-5d365fdb3a9c · outbound

This paper cites Anti-bcma car t-cell therapy bb2121 in relapsed or refractory multiple myeloma.

Statistical Operating Characteristics of Current Early Phase Dose Finding Designs with Toxicity and Efficacy in Oncology Anti-bcma car t-cell therapy bb2121 in relapsed or refractory multiple myeloma

Reference 22

Resolution: verified fuzzy; raw_fallback, observed 2026-08-12T21:30:35.664753Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-22T06:32:14.747728+00:00.

Observation 62754dc1-154e-444e-9ee2-2b9dca15e7af · outbound

This paper cites An adaptive dose-finding method using a change-point model for molecularly targeted agents in phase I trials.

Statistical Operating Characteristics of Current Early Phase Dose Finding Designs with Toxicity and Efficacy in Oncology An adaptive dose-finding method using a change-point model for molecularly targeted agents in phase I trials

Reference 23

Resolution: verified fuzzy; raw_fallback, observed 2026-08-12T21:30:35.484756Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-22T06:32:14.747728+00:00.

Observation 6b9e140d-6ac0-4436-ac80-9ac10060978f · outbound

This paper cites uTPI: A utility-based toxicity probability interval design for phase I/II dose-finding trials.

Statistical Operating Characteristics of Current Early Phase Dose Finding Designs with Toxicity and Efficacy in Oncology uTPI: A utility-based toxicity probability interval design for phase I/II dose-finding trials

Reference 24

Resolution: verified fuzzy; raw_fallback, observed 2026-08-12T21:30:35.304755Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-22T06:32:14.747728+00:00.

Observation 07269774-4e72-40a8-9e82-f5c054572906 · outbound

This paper cites Comparative review of novel model-assisted designs for phase I/II clinical trials.

Statistical Operating Characteristics of Current Early Phase Dose Finding Designs with Toxicity and Efficacy in Oncology Comparative review of novel model-assisted designs for phase I/II clinical trials

Reference 25

Resolution: verified fuzzy; raw_fallback, observed 2026-08-12T21:30:35.134756Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-22T06:32:14.747728+00:00.

Observation 6feee087-89fb-4d94-a8ec-c3467fc91b39 · outbound

This paper cites Pkboin-12: A bayesian optimal interval phase i/ii design incor- porating pharmacokinetics outcomes to find the optimal biological dose.

Statistical Operating Characteristics of Current Early Phase Dose Finding Designs with Toxicity and Efficacy in Oncology Pkboin-12: A bayesian optimal interval phase i/ii design incor- porating pharmacokinetics outcomes to find the optimal biological dose

Reference 26

Resolution: verified fuzzy; raw_fallback, observed 2026-08-12T21:30:34.974754Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-22T06:32:14.747728+00:00.

Observation f08c73a0-62d1-4a53-b61c-2aa10002a5c5 · outbound

This paper cites BOIN-ET: Bayesian optimal interval design for dose finding based on both efficacy and toxicity outcomes.

Statistical Operating Characteristics of Current Early Phase Dose Finding Designs with Toxicity and Efficacy in Oncology BOIN-ET: Bayesian optimal interval design for dose finding based on both efficacy and toxicity outcomes

Reference 27

Resolution: verified fuzzy; raw_fallback, observed 2026-08-12T21:30:34.794759Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-22T06:32:14.747728+00:00.

Observation 991eac41-3982-4c5d-a8ed-d9a0fd88639c · outbound

This paper cites TITE-BOIN-ET: time-to-event Bayesian optimal interval design to accelerate dose-finding based on both efficacy and toxicity outcomes.

Statistical Operating Characteristics of Current Early Phase Dose Finding Designs with Toxicity and Efficacy in Oncology TITE-BOIN-ET: time-to-event Bayesian optimal interval design to accelerate dose-finding based on both efficacy and toxicity outcomes

Reference 28

Resolution: verified fuzzy; raw_fallback, observed 2026-08-12T21:30:34.634840Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-22T06:32:14.747728+00:00.

Observation 3bcec4a4-3063-4f50-865f-70f8b63631ae · outbound

This paper cites gBOIN-ET: The generalized Bayesian optimal interval design for optimal dose-finding accounting for ordinal graded efficacy and toxicity in early clinical trials.

Statistical Operating Characteristics of Current Early Phase Dose Finding Designs with Toxicity and Efficacy in Oncology gBOIN-ET: The generalized Bayesian optimal interval design for optimal dose-finding accounting for ordinal graded efficacy and toxicity in early clinical trials

Reference 29

Resolution: verified fuzzy; raw_fallback, observed 2026-08-12T21:30:34.454828Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-22T06:32:14.747728+00:00.

Observation f1ddd41f-3848-4483-be4a-4bb673cc35bf · outbound

This paper cites TITE- gBOIN-ET: Time-to-event generalized Bayesian optimal interval design to accelerate dose-finding accounting for ordinal graded efficacy and toxicity outcomes.

Statistical Operating Characteristics of Current Early Phase Dose Finding Designs with Toxicity and Efficacy in Oncology TITE- gBOIN-ET: Time-to-event generalized Bayesian optimal interval design to accelerate dose-finding accounting for ordinal graded efficacy and toxicity outcomes

Reference 30

Resolution: verified fuzzy; raw_fallback, observed 2026-08-12T21:30:34.264835Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-22T06:32:14.747728+00:00.

Observation 1882351b-9fc4-46da-803b-08f386dd7f2b · outbound

This paper cites Dose-finding based on efficacy–toxicity trade-offs.

Statistical Operating Characteristics of Current Early Phase Dose Finding Designs with Toxicity and Efficacy in Oncology Dose-finding based on efficacy–toxicity trade-offs

Reference 31

Resolution: verified fuzzy; raw_fallback, observed 2026-08-12T21:30:34.094833Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-22T06:32:14.747728+00:00.

Observation e92ce4da-4f3c-4f2d-8318-1805fd63a6f2 · outbound

This paper cites Toxicities of immunotherapy for the practitioner.

Statistical Operating Characteristics of Current Early Phase Dose Finding Designs with Toxicity and Efficacy in Oncology Toxicities of immunotherapy for the practitioner

Reference 32

Resolution: verified fuzzy; raw_fallback, observed 2026-08-12T21:30:33.935141Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-22T06:32:14.747728+00:00.

Observation 6d6b669e-ff75-41dc-8b76-ff3dc8dec4ea · outbound

This paper cites Optimal biological dose selection in dose-finding trials with model-assisted designs based on ef- ficacy and toxicity: a simulation study.

Statistical Operating Characteristics of Current Early Phase Dose Finding Designs with Toxicity and Efficacy in Oncology Optimal biological dose selection in dose-finding trials with model-assisted designs based on ef- ficacy and toxicity: a simulation study

Reference 33

Resolution: verified fuzzy; raw_fallback, observed 2026-08-12T21:30:33.754751Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-22T06:32:14.747728+00:00.

Observation 6625a000-a4b7-4f78-bce0-20b5992273fe · outbound

This paper cites Keyboard: A novel Bayesian toxicity probability interval design for phase I clinical trials.

Statistical Operating Characteristics of Current Early Phase Dose Finding Designs with Toxicity and Efficacy in Oncology Keyboard: A novel Bayesian toxicity probability interval design for phase I clinical trials

Reference 34

Resolution: verified fuzzy; raw_fallback, observed 2026-08-12T21:30:33.574869Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-22T06:32:14.747728+00:00.

Observation ae1de6ff-6dc2-4821-851b-2482967fa092 · outbound

This paper cites Bayesian optimal interval design: A simple and well-performing design for phase I oncology trials.

Statistical Operating Characteristics of Current Early Phase Dose Finding Designs with Toxicity and Efficacy in Oncology Bayesian optimal interval design: A simple and well-performing design for phase I oncology trials

Reference 35

Resolution: verified fuzzy; raw_fallback, observed 2026-08-12T21:30:33.390403Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-22T06:32:14.747728+00:00.

Observation ccf4b27c-9f4e-4ed1-9e01-0ee0f619ef9d · outbound

This paper cites Model-assisted designs for early-phase clinical trials: simplicity meets superiority.

Statistical Operating Characteristics of Current Early Phase Dose Finding Designs with Toxicity and Efficacy in Oncology Model-assisted designs for early-phase clinical trials: simplicity meets superiority

Reference 36

Resolution: verified fuzzy; raw_fallback, observed 2026-08-12T21:30:33.214834Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-22T06:32:14.747728+00:00.

Observation cc75c906-9e76-44e4-ac48-43b4fbd68cf4 · outbound

This paper cites Adaptive designs for identifying optimal biological dose for molecularly targeted agents.

Statistical Operating Characteristics of Current Early Phase Dose Finding Designs with Toxicity and Efficacy in Oncology Adaptive designs for identifying optimal biological dose for molecularly targeted agents

Reference 37

Resolution: verified fuzzy; raw_fallback, observed 2026-08-12T21:30:33.055040Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-22T06:32:14.747728+00:00.

Observation c891c67c-b2f3-4655-a791-6a1ee7547ad8 · outbound

This paper cites 33 Characteristics of Early Phase Dose Finding Designs 34 TITE-BOIN12: A Bayesian phase I/II trial design to find the optimal biological dose with late-onset toxicity and efficacy.

Statistical Operating Characteristics of Current Early Phase Dose Finding Designs with Toxicity and Efficacy in Oncology 33 Characteristics of Early Phase Dose Finding Designs 34 TITE-BOIN12: A Bayesian phase I/II trial design to find the optimal biological dose with late-onset toxicity and efficacy

Reference 38

Resolution: malformed identifier; raw_fallback, observed 2026-08-12T21:30:32.874756Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-22T06:32:14.747728+00:00.

Pith citing papers

No inbound Pith citation observations are available.